Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “First or Second Line HER2-negative Breast Cancer”

11 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 11 of 11 results

Testing effectiveness (Phase 2)Study completedNCT02954055
What this trial is testing

MEtronomic TrEatment Option in Advanced bReast cAncer

Who this might be right for
Breast Cancer
ETOP IBCSG Partners Foundation 140
Large-scale testing (Phase 3)Study completedNCT04799249
What this trial is testing

Trilaciclib, a CDK 4/6 Inhibitor, in Patients Receiving Gemcitabine and Carboplatin for Metastatic Triple-Negative Breast Cancer (TNBC)

Who this might be right for
TNBC - Triple-Negative Breast CancerBreast Cancer
G1 Therapeutics, Inc. 194
Large-scale testing (Phase 3)Temporarily pausedNCT02037529
What this trial is testing

Eribulin Mesylate or Paclitaxel as First- or Second-Line Therapy in Treating Patients With Recurrent Stage IIIC-IV Breast Cancer

Who this might be right for
Breast AdenocarcinomaHER2/Neu NegativeInvasive Breast Carcinoma+2 more
Academic and Community Cancer Research United 201
Testing effectiveness (Phase 2)Study completedNCT01256762
What this trial is testing

Imetelstat in Combination With Paclitaxel (With or Without Bevacizumab) in Patients With Locally Recurrent or Metastatic Breast Cancer

Who this might be right for
Locally Recurrent or Metastatic Breast Cancer
Geron Corporation 166
Not applicableStudy completedNCT05399329
What this trial is testing

Study to Evaluate Real-world Effectiveness With Palbociclib Plus Endocrine Therapy as First-line/Second-line Treatment for HR+/HER2- Advanced Breast Cancer in Japan

Who this might be right for
Breast Cancer
Pfizer 688
Not applicableLooking for participantsNCT04030507
What this trial is testing

Screening Magnetic Resonance Imaging of the Brain in Patients With Breast Cancer

Who this might be right for
Breast CancerHER2-positive Breast CancerTriple Negative Breast Cancer+3 more
Dana-Farber Cancer Institute 214
Not applicableStudy completedNCT02551263
What this trial is testing

Eribulin Treatment as 1st-line or 2nd-line Chemotherapy for HER2-negative Hormone-resistant Inoperable or Recurrent Metastatic Breast Cancer

Who this might be right for
Breast Cancer
Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan 201
Testing effectiveness (Phase 2)Study completedNCT00696072
What this trial is testing

Randomized Phase II Trial of Letrozole With or Without Dasatinib as First and Second-line Treatment for Hormone Receptor-positive, HER2-negative Post-menopausal Breast Cancer That is Unresectable, Locally Recurrent or Metastatic

Who this might be right for
Metastatic Breast Cancer
Bristol-Myers Squibb 120
Large-scale testing (Phase 3)Study completedNCT01935492
What this trial is testing

8 Continuous vs 8 Intermittent Cycles in First and Second Line in HER2/Neu Neg Metastatic Breast Cancer

Who this might be right for
Human Epidermal Growth Factor 2 Negative Carcinoma of BreastMetastatic Breast Cancer
Borstkanker Onderzoek Groep 420
Testing effectiveness (Phase 2)Ended earlyNCT00852332
What this trial is testing

Docetaxel With or Without a Phytochemical in Treating Patients With Breast Cancer

Who this might be right for
Breast Cancer
Centre Jean Perrin 42
Post-approval studies (Phase 4)Study completedNCT01129336
What this trial is testing

Effect of Zoledronic Acid as Anti-Cancer Treatment in Metastatic Breast Cancer Patients

Who this might be right for
First or Second Line HER2-negative Breast CancerMetastatic Disease Without Bone Metastasis
Novartis Pharmaceuticals 44